Evidence map›Paper›PMID 33328345›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Predicting CAR-T cell Immunotherapy Success through ImmunoPET.

Alessia Volpe, Veronica L Nagle, Jason S Lewis, Vladimir Ponomarev

Abstract readComment
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Alessia VolpeDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3087-9178
Veronica L NagleWeill Cornell Medical College, New York, New York.
Jason S LewisDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7065-4534
Vladimir PonomarevDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. ponomarv@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Leveraging Pb-203/212 for the Theranostic Imaging and Therapy of Prostate CancerR35CA232130 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S. · 2019 to 2025
$8.2M
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell TherapyR01CA204924 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PONOMAREV, VLADIMIR · 2016 to 2020
$3.5M
Image-guided TRAIL-enhanced CAR T-cell immunotherapyR01CA220524 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PONOMAREV, VLADIMIR · 2018 to 2022
$2.9M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA204924NCI NIH HHS R01 CA220524NCI NIH HHS R35 CA232130
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR)-T cell therapy has generated unprecedented advances in the treatment of hematologic cancers, but readily translatable imaging approaches to visualize the

Indexed as

Hematologic NeoplasmsReceptors, Chimeric AntigenHumansImmunotherapyImmunotherapy, AdoptiveT-LymphocytesReceptors, Chimeric Antigen

Identifiers

PMID33328345
PMCPMC7887102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.